2014 Press Releases

Keyword Search
 
DateTitle  
07-Dec-2014ERYTECH reports additional positive Phase III results from clinical study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia
ERYTECH (Paris:ERYP)(Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative “tumor starvation” treatments for acute leukemia and other oncology indications with unmet medical needs, reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia. Positive top-line data of the study were made available end of September, and demonstrated that the Phase III GRASPIVOTALL clinical tr... 
Download PDFPrinter Friendly Version
23-Oct-2014ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments
ERYTECH Successfully Raises €30 Million for Expanding Its Therapeutic Indications in Oncology and Accelerating Its Clinical Developments Reserved capital increased with €30 million, of which 68% subscribed by US investors specialized in life sciences Following its recent success in acute leukemia, ERYTECH intends to speed up its development in the USA and in solid tumors October 23, 2014 02:00 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE... 
Download PDFPrinter Friendly Version
20-Oct-2014ERYTECH announces granting of new patent in the United States
ERYTECH Announces Granting of New Patent in the United States Patent that can strengthen positioning of ERY-ASP/GRASPA® by detecting the presence of neutralizing antibodies to asparaginase Patent delivered in the USA with patent term until 2029 Patent already granted in Europe, Australia and Singapore October 20, 2014 12:24 PM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News : ERYTECH (Paris:ERYP) (Euronext Paris: ... 
Download PDFPrinter Friendly Version
09-Oct-2014ERYTECH wins EuropaBio’s Most Innovative European Biotech SME Award 2014
ERYTECH wins EuropaBio’s Most Innovative European Biotech SME Award 2014 October 09, 2014 01:45 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH (Paris:ERYP)(Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, won EuropaBio’s Most Innovative European Biotech SME Award 2014. The award was... 
Download PDFPrinter Friendly Version
30-Sep-2014ERYTECH reports positive top-line Phase III results from clinical study with GRASPA® in Acute Lymphoblastic Leukemia
ERYTECH Reports Positive Top-Line Phase III Results from Clinical Study with GRASPA® in Acute Lymphoblastic Leukemia GRASPA® meets primary endpoints compared to native L-asparaginase: Statistically significant reduction of allergic reactions Statistically significant increase in duration of asparaginase activity Secondary endpoints confirm the favorable clinical efficacy of GRASPA® GRASPA® well tolerated by patients... 
Download PDFPrinter Friendly Version
02-Sep-2014ERYTECH business update and financial results for the first half of 2014
ERYTECH Business Update and Financial Results for the First Half of 2014 Clinical trials on track and two new studies started Shareholder base further internationalized Solid cash balance September 02, 2014 12:00 PM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News : ERYTECH (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation&rsq... 
Download PDFPrinter Friendly Version
27-Aug-2014ERYTECH announces second positive DSMB review of its Phase IIb study in Acute Myeloid Leukemia
ERYTECH Announces Second Positive DSMB Review of Its Phase IIb Study in Acute Myeloid Leukemia Independent experts have analyzed the safety data of the first 60 patients treated As in the first analysis, on the first 30 patients, the experts unanimously recommended continuation of the trial without modification August 27, 2014 12:00 PM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext... 
Download PDFPrinter Friendly Version
28-Jul-2014ERYTECH announces enrollment of first patient in Phase II study of ERY-ASP in pancreatic cancer
ERYTECH Announces Enrollment of First Patient in Phase II Study of ERY-ASP in Pancreatic Cancer July 28, 2014 12:00 PM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the enrollment of the first patient in it... 
Download PDFPrinter Friendly Version
22-Jul-2014ERYTECH announces enrollment of first patient in Phase I/II study of ERY-ASP in Acute Lymphoblastic Leukemia
ERYTECH Announces Enrollment of First Patient in Phase I/II Study of ERY-ASP in Acute Lymphoblastic Leukemia in the United States July 22, 2014 02:00 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces... 
Download PDFPrinter Friendly Version
16-Jul-2014ERYTECH provides financial update for Q2 2014
ERYTECH Provides Financial Update for Q2 2014 Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, provides a financial update for the second quarter of 2014. On June 30 2014, ERYTECH’s cash and cash equivalents amounted to € 12.3 million. This compares to a cash position of € 12... 
Download PDFPrinter Friendly Version
02-Jul-2014Bilan semestriel du contrat de liquidité confié à la société de bourse Bryan, Garnier & Co.
ERYTECH Pharma : Bilan semestriel du contrat de liquidité confié à la société de bourse Bryan, Garnier & Co. July 02, 2014 12:00 PM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris : FR0011471135 - ERYP), société biopharmaceutique française qui conçoit des traitements « affameur de tumeurs » innovants contre les leucémies aiguës et autres cancers pour lesquels les besoins médicaux restent insatisfaits, présente... 
Download PDFPrinter Friendly Version
18-Jun-2014ERYTECH appoints two new independent board members
ERYTECH appoints two new independent board members June 18, 2014 02:00 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces it has appointed Dr Martine George and Mrs Hilde Windels as new independent me... 
Download PDFPrinter Friendly Version
02-Jun-2014ERYTECH strengthens its intellectual property portfolio
ERYTECH Strengthens Its Intellectual Property Portfolio Patent « Medicament for the Treatment of Cancer of the Pancreas» allowed in Europe Patent « Lysis/Resealing Process for Preparing Erythrocytes» allowed in India June 02, 2014 11:45 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: “Medicament for the Treatment of Cancer of the Pancreas” Tweet this ERYTECH Pharma (Paris:ERYP) (Eurone... 
Download PDFPrinter Friendly Version
27-May-2014ERYTECH : ASSEMBLEE GENERALE MIXTE DU 17 JUIN 2014
ERYTECH : ASSEMBLEE GENERALE MIXTE DU 17 JUIN 2014 Modalités de mise à disposition des documents préparatoires May 27, 2014 03:48 PM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News : ERYTECH Pharma (Paris:ERYP) (Euronext Paris : FR0011471135 - ERYP), la société biopharmaceutique française qui développe des traitements innovants qui affament les tumeurs pour la leucémie aiguë et d'autres indications oncologiques ayant des besoins médicaux non... 
Download PDFPrinter Friendly Version
15-May-2014ERYTECH provides financial update for Q1 2014
ERYTECH Provides Financial Update for Q1 2014 Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, provides a financial update for the first quarter of 2014. On March 31 2014, ERYTECH’s cash and cash equivalents amounted to € 12.7 million. This compares to a cash position of € 15... 
Download PDFPrinter Friendly Version
06-May-2014ERYTECH receives authorization to start its Phase II clinical study in pancreatic cancer
ERYTECH Receives Authorization to Start Its Phase II Clinical Study in Pancreatic Cancer Phase II clinical study authorized in France Patient enrollment expected to start in Q2 2014 May 06, 2014 01:30 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other onco... 
Download PDFPrinter Friendly Version
29-Apr-2014ERYTECH provides business update and financial results for the full year 2013
ERYTECH Provides Business Update and Financial Results for the Full Year 2013 Strong operational performance with clinical programs on track Solid cash position Important news flow ahead April 29, 2014 12:00 PM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments ... 
Download PDFPrinter Friendly Version
09-Apr-2014ERYTECH adds a new product candidate to its tumor starvation development portfolio
ERYTECH adds a new product candidate to its tumor starvation development portfolio ERYTECH encapsulates a new enzyme, methionine-γ-lyase (MGL), in red blood cells Further broadening of the application of its proprietary technology in oncology April 09, 2014 01:30 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company ... 
Download PDFPrinter Friendly Version
02-Apr-2014ERYTECH receives Orphan Drug Designation by the FDA for ERY-ASP in Acute Myeloid Leukemia
ERYTECH Receives Orphan Drug Designation by the FDA for ERY-ASP in Acute Myeloid Leukemia Seventh Orphan Drug Designation (ODD) for ERYTECH All three of ERYTECH’s lead indications now benefit from ODD in Europe and the USA April 02, 2014 01:30 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: “We are very pleased by the granting of this additional Orphan Drug Designation” Tweet this ... 
Download PDFPrinter Friendly Version
26-Mar-2014Avenant au Contrat de Liquidité
ERYTECH : Avenant au Contrat de Liquidité March 26, 2014 03:00 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH (Paris:ERYP) (Euronext Paris : FR0011471135 - ERYP), société biopharmaceutique française qui conçoit des traitements innovants contre les leucémies aiguës et autres cancers, pour lesquels les besoins médicaux restent insatisfaits, annonce aujourd’hui un avenant à son contrat de liquidité signé le 30 avril 2013 avec Bryan, Garni... 
Download PDFPrinter Friendly Version
13-Feb-2014ERYTECH welcomes new US and European investors
ERYTECH Welcomes New US and European Investors Regulatory News: ERYTECH Pharma (Paris:ERYP) (FR0011471135), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, was informed today that certain of its historical institutional investors have sold part of their holdings to new specialized life sciences investors in the United States and in Europe. Under the deal, 17.5% of its capital originally held by ... 
Download PDFPrinter Friendly Version
28-Jan-2014ERYTECH PHARMA lance une souscription de BSPCE réservée à ses principaux cadres
ERYTECH PHARMA lance une souscription de BSPCE réservée à ses principaux cadres January 28, 2014 02:00 AM Eastern Standard Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH (Paris:ERYP) (Euronext Paris : FR0011471135 - ERYP), société biopharmaceutique française qui conçoit des traitements innovants contre les leucémies aiguës et autres cancers, pour lesquels les besoins médicaux restent insatisfaits, lance une souscription de BSPCE réservée à ses principaux cadres... 
Download PDFPrinter Friendly Version
27-Jan-2014ERYTECH gives feedback on its first Investor R&D Day and provides a financial and business update for Q4 2013
ERYTECH gives feedback on its first Investor R&D Day and provides a financial and business update for Q4 2013 January 27, 2014 02:00 PM Eastern Standard Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, held its first Investor R&D day and provides a financial an... 
Download PDFPrinter Friendly Version
15-Jan-2014ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML
ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML More than one third of patients enrolled and 18 investigation centers opened to date Authorizations to perform clinical trials in Finland and Spain internationalizes the study and is expected to further accelerate patient recruitment January 15, 2014 02:00 AM Eastern Standard Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTEC... 
Download PDFPrinter Friendly Version
07-Jan-2014ERYTECH positions its lead product in solid tumors and launches a Phase II clinical study in pancreatic cancer
ERYTECH Positions Its Lead Product in Solid Tumors and Launches a Phase II Clinical Study in Pancreatic Cancer Mode of action of ERYASP1 confirmed in different solid tumor indications Clinical trial application submitted for Phase II study in pancreatic cancer following EMA Scientific Advice Potential to target major unmet medical needs representing a multi-billion market opportunity January 07, 2014 01:00 AM Eastern Standard Time LYON, Fr... 
Download PDFPrinter Friendly Version
Top